CA-INVIVOSCRIBE
8.5.2024 16:01:30 CEST | Business Wire | Press release
A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT).
This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant.
A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population.
Dr. Hourigan, Director of the Virginia Tech FBRI Cancer Research Center in Washington, DC and Principal Investigator of the study, remarked, "This research underscores the value of pre-transplant testing for residual FLT3-ITD in adults with AML. The association of MRD test results with post-transplant outcomes opens up the potential of refining treatment strategies to improve survival."
Moving forward, the study calls for further research to explore alternative approaches for high-risk populations who may not benefit from current standard care protocols.
Dr. Jeff Miller, CEO/CSO at Invivoscribe commented, "We are thrilled to see the remarkable association of clinical outcomes that were so clearly delineated using our research use only test and software. This research study enhances our understanding of AML monitoring and treatment."
About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized research reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. For additional information, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on Linked In.
1. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia, Dillon et al, JAMA Oncology, Published online May 2, 2024.
2. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, Dillon et al, JAMA 2023; 329 (9): 745-755
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508192559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates14.9.2026 15:40:00 CEST | Press release
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914150232/en/ Students from Qatar, Canada and Mexico during their visit to the University of Toronto as part of the Doha Debates Town Hall experience in Canada. (Photo: AETOSWire) An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives. This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of sp
Matt Shafer Joins Golub Capital as Head of Golub Equity Continuation Partners14.9.2026 15:30:00 CEST | Press release
Golub Capital (“the Firm”) today announced the appointment of Matt Shafer as Managing Director and Head of the Firm’s GP-led private equity secondaries strategy, Golub Equity Continuation Partners (“GECP”). In this role, he will be responsible for leading the continued growth and development of the strategy and helping expand the Firm’s equity investment capabilities. Matt will work closely with Greg Cashman, Vice Chair and Co-Head of Golub Capital’s Sponsor Finance practice, to expand Golub Capital’s activity in this growing market. Shafer brings nearly three decades of global experience as an investor, financier and advisor working with private equity firms. He was most recently Head of Capital Solutions and U.S. Private Equity at Northleaf Capital Partners. In this role, Shafer helped lead the firm’s private equity investment activities, including secondaries, co‑investments and structured capital. Prior to Northleaf, he was Partner and Head of Americas Private Equity at Vision Capi
HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI14.9.2026 15:19:00 CEST | Press release
Investment positions AMRA to meet growing global demand for precise, scalable advanced muscle and fat imaging in clinical research and healthcare. AMRA Medical today announced an investment from HealthCap, one of Europe’s leading life science venture capital firms. This milestone marks a significant step in AMRA’s growth, underscoring market confidence in the company’s vision to transform the measurement and understanding of muscle and fat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914838191/en/ HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI HealthCap’s backing comes as quantitative MRI gains vital importance in understanding how fat distribution and muscle composition influence disease, treatment response, and patient outcomes. Built on over 15 years of research, AMRA’s proprietary methods move beyond conventional metrics—like weight, and BMI and muscle function tests—to provide th
Morgan Stanley Inclusive & Sustainable Ventures Announces 2026 Global Cohort of Innovators14.9.2026 15:00:00 CEST | Press release
Accelerator focuses on impact across four areas: Environment, Health & Wellbeing, Economic Empowerment, and Education & Human Capital 20 startups and four nonprofits in the Americas and EMEA were selected from thousands of applicants Five-month program provides capital, mentorship and access to the firm’s global network Morgan Stanley (NYSE: MS) today announced the 2026 global cohort of its Inclusive & Sustainable Ventures (MSISV). This year’s cohort includes 20 startups and four nonprofits across the Americas and Europe, the Middle East and Africa (EMEA) participating in the firm's five-month accelerator program designed to help early-stage innovators develop and scale their impact. Selected from thousands of applications, the 24 organizations will receive a $150,000 equity investment, or grant funding for nonprofits, as well as access to a curated curriculum, networking opportunities and office space. Founders will work closely with a dedicated MSISV team, Entrepreneurs in Residence
S&P Global Leads Strategic Investment in Kaiko, Extending Series B to $110 Million14.9.2026 14:00:00 CEST | Press release
Global financial institutions are funding the leading provider of data services for 24/7 onchain finance, and establishing a Kaiko-chaired industry working group to focus on data infrastructure for tokenized markets. Kaiko, the regulated provider of data services for onchain finance, today announced that S&P Global has led a strategic investment in the company, extending Kaiko's Series B to $110 million. S&P Global was joined in the round by additional strategic investors: BNP Paribas, Bpifrance, Broadridge, Canton Foundation, Coinbase Ventures, DRW Venture Capital, Nasdaq Ventures, Royal Bank of Canada, Stellar, and Susquehanna Private Equity Investments. Existing shareholders Anthemis, Point Nine, and Revaia, also participated in the extension. The support of investors from across the financial ecosystem reflects a shift already underway: the institutions that run today's capital markets are now funding the data infrastructure required to operate tokenized markets. Alongside their in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom